Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350828 · ClinicalTrials.gov registry record
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
A clinical trial of Cystic Fibrosis, sponsored by Nicole Hamblett.
- Active
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT03350828: Active study of Cystic Fibrosis, sponsored by Nicole Hamblett.
NCT03350828 is a study of Cystic Fibrosis that is active but no longer recruiting, run by Nicole Hamblett. The registered enrollment target is 5,000 participants, above the 150-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (3233% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03350828, a study of Cystic Fibrosis, is active but no longer recruiting, sponsored by Nicole Hamblett.
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Primary Outcome
mean change in sweat chloride pre- to post- modulator therapy
Conditions Studied
Study Locations (20)
Florida
- University of Florida - Gainesville
- The Nemours Children's Clinic - Orlando - Orlando
- Nemours Children's Clinic - Pensacola - Pensacola
California
- University of California San Diego - La Jolla
- Childrens Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
- National Jewish Health - Denver
Georgia
- Children's Healthcare of Atlanta and Emory University - Atlanta
- Emory University - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Alabama
- The Children's Hospital Alabama, University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03350828 still lists
NCT03350828 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 150-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (3233% higher).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT03350828 names 20 study sites across 13 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03350828 about?
NCT03350828 is a clinical study titled "CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes". This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapie...
What is the current status of trial NCT03350828?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2018-01-15. Estimated completion is 2026-12-31.
What conditions does trial NCT03350828 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
Who is sponsoring clinical trial NCT03350828?
This trial is sponsored by Nicole Hamblett, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03350828 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03350828's enrollment target sits among peer trials
5,000 1st of 169 higher than 169 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI